Furthermore, differences in the role of distinct molecular subtypes of breast cancer on the bone niche, such as luminal-like or epidermal growth factor receptor 2 (HER2) enriched breast cancer cell lines, could be investigated in future studies. This evidence concerns the gene ERBB2 and breast carcinoma.